SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas

Oncogene

Volumn 32, Issue 18, 2013, Pages 2365-2371

  Jones, K B ^a,b   Su, L ^c   Jin, H ^a,b   Lenz, C ^a,b   Randall, R L ^a,b   Underhill, T M ^c   Nielsen, T O ^c   Sharma, S ^a,b   Capecchi, M R ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

apoptosis; chemotherapy; mouse model; synovial sarcoma; targeted therapy

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; BCL2 RELATED PROTEIN A1; BH3 PROTEIN; DOXORUBICIN; PEPTIDOMIMETIC AGENT; PROTEIN BCL 2; PROTEIN MCL 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BCL2A1 ONCOGENE; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; FUSION GENE; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MCL1 ONCOGENE; MITOCHONDRION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; SARCOMA CELL; SENSITIVITY ANALYSIS; SS18 SSX FUSION GENE; SYNOVIAL SARCOMA; TRANSCRIPTION INITIATION;

ACTIVATING TRANSCRIPTION FACTOR 2; ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MITOCHONDRIA; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCL-2; SARCOMA, SYNOVIAL; SULFONAMIDES;

MURINAE;

EID: 84877584164     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.247     Document Type: Article

References (21)

1. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-140.
2. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007; 11: 375-388.
3. Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res 2009; 69: 3657-3664.
4. Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin SC et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012; 21: 333-347.
5. Hirakawa N, Naka T, Yamamoto I, Fukuda T, Tsuneyoshi M. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol 1996; 27: 1060-1065.
6. Sun B, Sun Y, Wang J, Zhao X, Wang X, Hao X. Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma. Eur J Cancer Prev 2006; 15: 258-265.
7. Knosel T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer 2010; 46: 1170-1176.
8. Mancuso T, Mezzelani A, Riva C, Fabbri A, Dal L, Sampietro Bo, G. et al. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 2000; 80: 805-813.
9. Joyner DE, Albritton KH, Bastar JD, Randall RL. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FUSY-1 synovial sarcoma cell line. J Orthop Res 2006; 24: 474-480.
10. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
11. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
12. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
13. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304-3313.
14. Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 2010; 9: 545-557.
15. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31-36.
16. Nakayama R, Mitani S, Nakagawa T, Hasegawa T, Kawai A, Morioka H et al. Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol 2010; 34: 1599-1607.
17. Liu TM, Guo XM, Tan HS, Hui JH, Lim B, Lee EH. Zinc-finger protein 145, acting as an upstream regulator of SOX9, improves the differentiation potential of human mesenchymal stem cells for cartilage regeneration and repair. Arthritis Rheum 2011; 63: 2711-2720.
18. Nakayama R, Nemoto T, Takahashi H, Ohta T, Kawai A, Seki K et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 2007; 20: 749-759.
19. Joshi SK, Hashimoto K, Koni PA. Induced DNA recombination by Cre recombinase protein transduction. Genesis 2002; 33: 48-54.
20. Su L, Cheng H, Sampaio AV, Nielsen TO, Underhill TM. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene 2010; 29: 4352-4361.
21. Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K et al. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett 2004; 204: 105-113.